Literature DB >> 25216787

Nitric oxide in the normal kidney and in patients with diabetic nephropathy.

Paolo Tessari1.   

Abstract

Nitric oxide (NO) is a gas with biological and regulatory properties, produced from arginine by the way of nitric oxide synthases (NOS), and with a very short half-life (few seconds). A "coupled" NOS activity leads to NO generation, whereas its uncoupling produces the reactive oxygen species peroxynitrite (ONOO(-)). Uncoupling is usually due to inflammation, oxidative stress, decreased cofactor availability, or excessive NO production. Competitive inhibitors of NO production are post-translationally methylated arginine residues in proteins, which are constantly released into the circulation. NO availability is altered in many clinical conditions associated with vascular dysfunction, such as diabetes mellitus. The kidney plays an important role in body NO homeostasis. This article provides an overview of current literature, on NO production/availability, with a focus on diabetic nephropathy. In diabetes, NO availability is usually decreased (with exception of the early, hyper filtration phase of nephropathy in Type 1 diabetes), and it could constitute a factor of the generalized vasculopathy present in diabetic nephropathy. NO generation in Type 2 diabetes with nephropathy is inversely associated with the dimethyl-arginine concentrations, which are therefore important modulators of NO synthesis independently from the classic stimulatory pathways (such as the insulin effect). A disturbed NO metabolism is present in diabetes associated with nephropathy. Although modulation of NO production is not yet a common therapeutical strategy, a number of yet experimental compounds need to be tested as potential interventions to treat the vascular dysfunction and nephropathy in diabetes, as well as in other diseased states. Finally, in diabetic nephropathy NO deficiency may be associated to that of hydrogen sulfide, another interesting gaseous mediator which is increasingly investigated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25216787     DOI: 10.1007/s40620-014-0136-2

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  121 in total

1.  Biphasic vasodilator action of troglitazone on the renal microcirculation.

Authors:  Shuji Arima; Kentaro Kohagura; Kazuhisa Takeuchi; Yoshihiro Taniyama; Akira Sugawara; Yukio Ikeda; Michiaki Abe; Ken Omata; Sadayoshi Ito
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

2.  Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells.

Authors:  Daniela Verzola; Maria Bianca Bertolotto; Barbara Villaggio; Luciano Ottonello; Franco Dallegri; Guido Frumento; Valeria Berruti; Maria Teresa Gandolfo; Giacomo Garibotto; Giacomo Deferran
Journal:  J Investig Med       Date:  2002-11       Impact factor: 2.895

Review 3.  Hydrogen sulfide and the liver.

Authors:  Sarathi Mani; Wei Cao; Lingyun Wu; Rui Wang
Journal:  Nitric Oxide       Date:  2014-02-26       Impact factor: 4.427

4.  Apoptosis in the kidneys of patients with type II diabetic nephropathy.

Authors:  D Verzola; M T Gandolfo; F Ferrario; M P Rastaldi; B Villaggio; F Gianiorio; M Giannoni; L Rimoldi; F Lauria; M Miji; G Deferrari; G Garibotto
Journal:  Kidney Int       Date:  2007-09-12       Impact factor: 10.612

5.  Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9.

Authors:  Sourav Kundu; Sathnur B Pushpakumar; Aaron Tyagi; Denise Coley; Utpal Sen
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-30       Impact factor: 4.310

6.  One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Authors:  Markolf Hanefeld; Paolo Brunetti; Guntram H Schernthaner; David R Matthews; Bernard H Charbonnel
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 7.  Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis.

Authors:  Bruno Schmidt Dellamea; Lana Catani Ferreira Pinto; Cristiane Bauermann Leitão; Katia Gonçalves Santos; Luis Henrique Santos Canani
Journal:  BMC Med Genet       Date:  2014-01-16       Impact factor: 2.103

8.  Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects.

Authors:  Keisuke Ishizawa; Yuki Izawa-Ishizawa; Noriko Yamano; Maki Urushihara; Takumi Sakurada; Masaki Imanishi; Shoko Fujii; Asami Nuno; Licht Miyamoto; Yoshitaka Kihira; Yasumasa Ikeda; Shoji Kagami; Hiroyuki Kobori; Koichiro Tsuchiya; Toshiaki Tamaki
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

Review 9.  What is the real physiological NO concentration in vivo?

Authors:  Catherine N Hall; John Garthwaite
Journal:  Nitric Oxide       Date:  2009-07-12       Impact factor: 4.427

10.  Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.

Authors:  Hanning You; Ting Gao; Timothy K Cooper; Sidney M Morris; Alaa S Awad
Journal:  Kidney Int       Date:  2013-06-12       Impact factor: 10.612

View more
  20 in total

Review 1.  Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials.

Authors:  Noori Al-Waili; Hamza Al-Waili; Thia Al-Waili; Khelod Salom
Journal:  Redox Rep       Date:  2017-03-09       Impact factor: 4.412

2.  Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats.

Authors:  Aly M Abdelrahman; Yousuf Al Suleimani; Asem Shalaby; Mohammed Ashique; Priyadarsini Manoj; Badreldin H Ali
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-25       Impact factor: 3.000

Review 3.  Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy.

Authors:  Giacomo Garibotto; Annalisa Carta; Daniela Picciotto; Francesca Viazzi; Daniela Verzola
Journal:  J Nephrol       Date:  2017-09-20       Impact factor: 3.902

4.  The role of nitric oxide in sepsis-associated kidney injury.

Authors:  Filipe Rodolfo Moreira Borges Oliveira; Jamil Assreuy; Regina Sordi
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 5.  Acute Kidney Injury and Progression of Diabetic Kidney Disease.

Authors:  Samuel Mon-Wei Yu; Joseph V Bonventre
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

Review 6.  Mini-review: diabetic renal complications, a potential stinky remedy.

Authors:  Utpal Sen; Sathnur Pushpakumar
Journal:  Am J Physiol Renal Physiol       Date:  2015-11-04

7.  Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.

Authors:  John P Hanrahan; Ian H de Boer; George L Bakris; Phebe J Wilson; James D Wakefield; Jelena P Seferovic; Jennifer G Chickering; Yueh-Tyng Chien; Kenneth Carlson; Michael D Cressman; Mark G Currie; G Todd Milne; Albert T Profy
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-16       Impact factor: 8.237

Review 8.  Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets.

Authors:  Stephanie Toth-Manikowski; Mohamed G Atta
Journal:  J Diabetes Res       Date:  2015-04-30       Impact factor: 4.011

Review 9.  A more tubulocentric view of diabetic kidney disease.

Authors:  Letizia Zeni; Anthony G W Norden; Giovanni Cancarini; Robert J Unwin
Journal:  J Nephrol       Date:  2017-08-24       Impact factor: 3.902

10.  Comparison of Antioxidative Effects of Insect Tea and Its Raw Tea (Kuding Tea) Polyphenols in Kunming Mice.

Authors:  Xin Zhao; Jia-Le Song; Ruokun Yi; Guijie Li; Peng Sun; Kun-Young Park; Huayi Suo
Journal:  Molecules       Date:  2018-01-19       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.